Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma.
about
Kinase inhibitors as potential agents in the treatment of multiple myeloma.A Hypoxia-Targeted Boron Neutron Capture Therapy Agent for the Treatment of GliomaTris (dibenzylideneacetone) dipalladium: a small-molecule palladium complex is effective in inducing apoptosis in chronic lymphocytic leukemia B-cells.MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myelomaNovel concept of the smart NIR-light-controlled drug release of black phosphorus nanostructure for cancer therapy.Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma.
P2860
Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma.
@en
Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma.
@nl
type
label
Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma.
@en
Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma.
@nl
prefLabel
Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma.
@en
Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma.
@nl
P2093
P2860
P1433
P1476
Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma.
@en
P2093
Abdel Kareem Azab
Barbara Muz
Micah Luderer
Pilar de la Puente
P2860
P304
P356
10.3109/10428194.2015.1099645
P50
P577
2015-11-16T00:00:00Z